Major depression and its treatment: microRNAs as peripheral biomarkers of diagnosis and treatment response.

TitleMajor depression and its treatment: microRNAs as peripheral biomarkers of diagnosis and treatment response.
Publication TypeJournal Article
Year of Publication2018
AuthorsLopez JPablo, Kos A, Turecki G
JournalCurr Opin Psychiatry
Volume31
Issue1
Pagination7-16
Date Published2018 Jan
ISSN1473-6578
Abstract

PURPOSE OF REVIEW: Major depressive disorder (MDD) is among the most prevalent and disabling medical conditions worldwide. Despite its considerable burden, our understanding of its pathophysiology remains rudimentary, and a validated biomarker has yet to be identified. Antidepressants are the most common treatment for MDD, yet roughly one-third of patients experience an inadequate response. Thus, there is a great need for not only identifying biomarkers of MDD but also those that can predict and monitor or just monitor response to treatment.RECENT FINDINGS: MicroRNAs (miRNAs) act as endogenous fine-tuners and on-off switches of gene expression. Several lines of evidence now suggest that miRNAs are involved in the pathogenesis of neuropsychiatric disorders. As such, miRNAs offer great hope as biomarkers of disease and response to treatment.SUMMARY: In this review, we discuss the growing field, investigating peripheral miRNAs as potential biomarkers of major depression and treatment response. A noninvasive and validated biomarker of MDD or treatment response will help clinicians guide treatment selection. Ultimately, these findings provide important steps in the development of early diagnostic tools, preventive strategies, and effective pharmacological treatment for psychiatric disorders.

DOI10.1097/YCO.0000000000000379
Alternate JournalCurr Opin Psychiatry
PubMed ID29076893